For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study published in the March issue of The Lancet ...
Mar 13, 2023
0
6
A major international trial published in The Lancet Oncology has looked at studies from 13 head and neck cancer centers from nine countries around the world. Using the data of 7,895 patients, a research team has found that ...
Feb 13, 2023
0
52
Led by the Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), an international group of the world's top clinicians in managing nasopharyngeal carcinoma ...
Feb 6, 2023
0
5
Results from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free survival (PFS) times in patients with triple-negative breast cancer (TNBC) that has a "BRCA-like" ...
Jan 31, 2023
0
34
Researchers from the University of Chicago Medicine Comprehensive Cancer Center and colleagues in Poland report promising results from their ongoing ATLAS trial, published on January 12, 2023 in the journal Lancet Oncology.
Jan 13, 2023
0
25
A subcutaneously implanted, catheter-pump system capable of chronic convection-enhanced delivery (CED) of topotecan is well tolerated and active for patients with recurrent glioblastoma, according to a study published in ...
Dec 1, 2022
0
2
The COVID-19 pandemic has exposed weaknesses in cancer health systems and in the cancer research landscape across Europe, which, if not addressed as a matter of urgency, will set back cancer outcomes by almost a decade. In ...
Nov 16, 2022
0
60
A significant obstacle to treating brain cancer is not the cancer, but the brain itself.
Nov 11, 2022
0
62
An advanced radiotherapy technique can be used to safely treat prostate cancer patients in as little as one to two weeks, compared with the current standard, which takes one to two months.
Nov 9, 2022
0
69
Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor control and no increased ...
Nov 4, 2022
0
51
